AOD-9604 10mg research peptide UK is the advanced-format HGH fragment for established UK laboratory programmes requiring full dose-response concentration gradients and multi-arm beta-3 adrenergic metabolic pathway studies. ≥98% purity. Janoshik tested. Same-day dispatch. Research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
AOD-9604 10mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
AOD-9604 10mg Research Peptide UK
AOD-9604 10mg is the advanced-format version of the most studied selective lipolysis research compound in the UK metabolic peptide market. Identical compound to the 5mg format — C78H123N23O23S2, approximately 1,817 Da, Tyr-hGH Fragment 177-191, selective beta-3 adrenergic receptor agonist — but providing the research capacity for full dose-response concentration gradients, multi-arm experimental designs, and extended single-batch longitudinal metabolic studies.
The aod 9604 10mg research format becomes the appropriate choice when the experimental design has been validated at the 5mg pilot level and the programme requires: full dose-response concentration gradients across five or more treatment arms from a single batch; parallel comparative studies running AOD-9604 10mg alongside AOD-9604 5mg, HGH Fragment 176-191 (unmodified), or full-length hGH as reference compounds; or extended longitudinal metabolic studies where inter-batch variability would compromise data consistency across weeks or months of experimental work.
The mechanism of the AOD 9604,10mg peptide is identical to the 5mg format: selective beta-3 AR activation without GHR binding and without IGF-1 stimulation. The IGF-1 independence is the most important research advantage — it eliminates IGF-1 as a confounding variable and allows clean investigation of lipolytic pathway activity in isolation. Alongside lipolysis stimulation, published preclinical literature documents inhibition of lipogenesis in laboratory adipocyte models, providing a dual-action metabolic profile.
For multi-compound metabolic research programmes, IGF-1 LR3 1mg operates through the IGF-1 receptor (IGF-1R) rather than beta-3 AR, providing a mechanistically non-overlapping growth factor probe that can be used as an independent variable alongside AOD-9604 10mg in the same experimental system. For GH axis upstream research alongside metabolic studies, Tesamorelin 10mg or CJC-1295 Without DAC 10mg provides the GHRH pathway dimension.
For complete format comparison and full mechanism detail, see the AOD-9604 10mg research guide on the Ascend Peptides UK blog.
All batches tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirms N-terminal Tyr intact.
For laboratory handling purposes, AOD-9604 may be reconstituted using bacteriostatic water or other suitable aqueous solvents, depending on experimental design requirements. Store at -20°C.
WADA Status: Listed on WADA Prohibited List.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
